Thomas Altier Sells 10,955 Shares of Phreesia (NYSE:PHR) Stock

Phreesia (NYSE:PHR) CFO Thomas Altier sold 10,955 shares of the company’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $32.85, for a total value of $359,871.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Phreesia stock opened at $32.61 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 4.01 and a current ratio of 4.01. The stock’s 50 day moving average is $28.93 and its 200 day moving average is $27.71. Phreesia has a twelve month low of $22.05 and a twelve month high of $34.39.

Phreesia (NYSE:PHR) last released its quarterly earnings data on Tuesday, December 10th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.03. The business had revenue of $32.80 million during the quarter, compared to the consensus estimate of $29.48 million. The firm’s revenue was up 32.3% on a year-over-year basis. On average, research analysts anticipate that Phreesia will post -0.43 EPS for the current year.

Several research firms recently weighed in on PHR. Zacks Investment Research downgraded Phreesia from a “buy” rating to a “hold” rating in a research note on Tuesday. Cantor Fitzgerald began coverage on Phreesia in a research note on Wednesday, January 8th. They issued an “overweight” rating and a $32.00 price target on the stock. KeyCorp began coverage on Phreesia in a research note on Thursday, January 30th. They issued an “overweight” rating and a $36.00 price target on the stock. ValuEngine downgraded Phreesia from a “buy” rating to a “hold” rating in a research note on Thursday, October 31st. Finally, Raymond James began coverage on Phreesia in a research note on Thursday, December 19th. They issued an “outperform” rating and a $33.00 price target on the stock. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Phreesia has a consensus rating of “Buy” and an average target price of $31.78.

Hedge funds have recently added to or reduced their stakes in the stock. Rhumbline Advisers bought a new stake in shares of Phreesia in the third quarter valued at $208,000. Emerald Advisers LLC purchased a new position in shares of Phreesia in the third quarter valued at $1,036,000. Russell Investments Group Ltd. purchased a new position in shares of Phreesia in the third quarter valued at $47,000. Tower Research Capital LLC TRC purchased a new position in shares of Phreesia in the third quarter valued at $68,000. Finally, Massachusetts Financial Services Co. MA purchased a new position in shares of Phreesia in the third quarter valued at $11,955,000. 51.49% of the stock is currently owned by institutional investors and hedge funds.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company's Phreesia Platform offers a suite of solutions to manage the patient intake process and an integrated payments solution for processing of patient payments.

Featured Story: Cryptocurrencies

Insider Buying and Selling by Quarter for Phreesia (NYSE:PHR)

Receive News & Ratings for Phreesia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phreesia and related companies with MarketBeat.com's FREE daily email newsletter.